Michael Farrell
Hematology & Oncology · Middletown, CTNPI 1841396959
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.7%), food and beverage and education — rather than concentrated in one kind of arrangement. Mckesson Specialty Care Distribution, LLC accounts for 63.7% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2020 at $1,056 and has fallen 73.3% since, to $282 in 2025. That places this record below the midpoint for hematology & oncology clinicians in CT, where the typical reported total is $1,376.
Across 30 payments — averaging $64.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mckesson Specialty Care Distribution, LLC$1K
- Bristol Myers Squibb$122
- Sanofi-aventis U.S. LLC$100
- E.r. Squibb & Sons, L.L.C.$95
- Genentech USA, Inc.$85
- Merck$46
- plus $259 from 10 others
What the payments were for
- Consulting fees$1,00552%
- Food & beverage$81742%
- Education$1246%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mckesson Specialty Care Distribution, LLC | 4 | $1,238 |
| Bristol Myers Squibb | 4 | $122 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| E.r. Squibb & Sons, L.L.C. | 2 | $95 |
| Genentech USA, Inc. | 4 | $85 |
| Merck | 3 | $46 |
| Daiichi Sankyo Inc. | 2 | $41 |
| Johnson & Johnson | 2 | $36 |
| Ipsen Biopharmaceuticals, Inc | 1 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| GSK | 1 | $25 |
| AstraZeneca | 1 | $24 |
| Coherus Oncology, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Seagen Inc. | 1 | $12 |
| Gilead | 1 | $12 |
How this compares
$1,946 in reported general payments places this provider in the 50th percentile of 163 hematology & oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 29 | $532,324 |
| XtandiEnzalutamide | 39 | $470,582 |
| ImbruvicaIbrutinib | 19 | $305,943 |
| InlytaAxitinib | 11 | $227,141 |
| NubeqaDarolutamide | 14 | $187,348 |
| EliquisApixaban | 39 | $36,412 |
| Abiraterone Acetate | 26 | $22,957 |
| XareltoRivaroxaban | 18 | $16,938 |
| Tamoxifen Citrate | 103 | $2,980 |
| Anastrozole | 120 | $1,844 |
| Hydroxyurea | 30 | $827 |
| Acyclovir | 23 | $460 |
| Warfarin Sodium | 28 | $459 |
| Gabapentin | 26 | $452 |
| Prednisone | 75 | $348 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLynparza | $24 | $532,32429 claims |
| Astellas Pharma US IncXtandi | $22 | $470,58239 claims |
| Johnson & JohnsonXarelto | $36 | $16,93818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 163 hematology & oncology providers in Connecticut.
Other hematology & oncology in Middletown
- Amer ZeidanNew Haven$807K
- Biree AndemariamFarmington$646K
- Paul WeinsteinStamford$288K
- Walid ShaibNew Haven$217K
- Madhavi GorusuHartford$207K
- Dinesh KapurNorwich$201K
- Scott HuntingtonNew Haven$163K
- Nataliya UbohaNew Haven$124K
- Michael CecchiniNew Haven$103K
- Justine RyuOrange$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.